JN
Johnson & Johnson
JNJ.DE · XETRA
235.45 € -1.59% (-3.80 €)
1M +4.43%
Market Cap $648.1B
P/E Ratio 30.82x
Div. Yield 1.93%
ROE 25.72%
Bulios Fair Price
158.96 €
32.5% downside
Current Price
235.45 €
Undervalued Fair Value Overvalued
According to Bulios Fair Price, JNJ.DE is currently overvalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Analysis
An AI report on the business, its finances, valuation, sentiment, news and risks - written in a few minutes.
Piotroski F-Score Strong
8/9Valuation
35 /100
Fair P/E 30.82x
PEG 0.27x
EV/EBITDA 20.10x
Growth
47 /100
Stable EPS growth 17.90%
Book val. growth 2.02%
Rev. growth 0.26%
Profitability
100 /100
Strong Gross margin 72.78%
FCF margin 22.71%
Net margin 21.48%
Quality
80 /100
Excellent ROIC 13.97%
Asset turnover 0.49x
ROE 25.72%
Debt
81 /100
Low Debt/Equity 0.58x
Net debt/EBITDA 0.85x
Current ratio 1.09x
Stability
46 /100
Moderate Beta 0.24x
Profitable years 6
Rev. volatility 8.98%
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about JNJ.DE
Online
Sector
Healthcare
Industry
Drug Manufacturers - General
CEO
Joaquin Duato
Employees
138,200
Headquarters
New Brunswick
Upcoming events
13 OCT
Earnings
Upcoming earnings report